ClinicalTrials.gg
Active, not recruitingNCT07391137CRUCIAL-RUpdated Feb 9, 2026

CRUCIAL-R Study : Cruciferous Vegetables Dietary Regimen in NMIBC

An interventional study of Cruciferae intake diet and Habituary dietary regimen in Recurrence Free Survival and Bladder Cancer Recurrence, sponsored by S. Andrea Hospital. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-09.

Primary conditionNon-Muscle Invasive Bladder NeoplasmsRegistry: Urinary Bladder NeoplasmsReclassifiedWhy we changed it
Registry
Urinary Bladder Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Non-Muscle Invasive Bladder Neoplasms
Why
  1. The study's title name Non-Muscle Invasive Bladder Neoplasms, a narrower term within Urinary Bladder Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by S. Andrea Hospital · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy — 12 open to participants now, 15 under way, 5 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · Italy.

Planned enrollment
11th of 27
250 · median 190
Started
2025
with 5 others
No phase
7 of 30
3 open now
Primary completion
2026-11
later than 1 of 14 live
Registered
27th of 30
by date

Among the 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy, this one is the 11th largest by planned enrollment of the 27 interventional ones that give a count, is one of 6 that started in 2025, is one of 7 with no phase, reaches primary completion later than 1 of the 14 other live ones, and was the 27th registered.

Non-Muscle Invasive Bladder Neoplasms

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

12 of the 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

Emerging evidence highlights the importance of nutrition in modulating cancer-related pathways, suggesting that specific dietary patterns and food choices may influence cancer risk. A protective role has been suggested for high consumption of vegetables, non-saturated fat oil (Mediterranean diet), fruits, and flavonoids [10-13]. In contrast, a diet rich in saturated fats and meat has been linked to an increased risk of BC [14,15]. Particularly, the consumption of vegetables of the Cruciferae family, such as broccoli, cauliflower, brussels sprouts, cabbage, kale, turnips, and others, has gathered attention for their potential protective effects due to their bioactive compounds: Isothiocyanates (ITCs). Dietary ITCs are a group of phytochemicals with multifaceted anticancer mechanisms primarily derived from cruciferous vegetables (CV) as glucosinolates and converted to ITCs by the action of the enzyme myrosinase [16]. Organic ITCs, particularly allyl isothiocyanate (AITC), benzyl isothiocyanate (BITC), phenethyl isothiocyanate (PEITC), and sulforaphane (SF), are among the most extensively studied cancer chemopreventive agents. Several mechanisms for ITCs in protection against carcinogenesis have been proposed, which include inhibition of carcinogen activation and promotion of detoxification, induction of cell cycle arrest and activation of apoptosis, inhibition of cancer cell invasion, modulation of the tumor microenvironment, inhibition of self-renewal of stem cells, rearrangement of energy metabolism and regulation of microbial homeostasis [17-22].

Aims Primary Objective

  • To evaluate the effect, in terms of recurrence-free survival (RFS) at 1 year, of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, or Very High-grade Non-Muscle Invasive Bladder Cancer treated with BCG (defined as the standard of care - SOC).

Secondary Objectives

  • To evaluate the effect, in terms of time to recurrence, of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, and Very High-grade Non-Muscle Invasive Bladder Cancer.
  • To evaluate the effect, in terms of recurrence-free survival (RFS), of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, and Very High-grade Non-Muscle Invasive Bladder Cancer with prior recurrence ≤1/yr and \<4 tumors (according to 2016 EORTC risk stratification for patients treated with maintenance BCG).
  • To evaluate the impact of high Cruciferous vegetable consumption on urinary ITC levels.
  • To evaluate the impact of high Cruciferous vegetable consumption on quality of life (QoL).
Read the detailed description

Background Bladder cancer (BC) ranks as the seventh most common cancer among men globally and the tenth when both genders are considered. The majority (up to 75%) of newly diagnosed BC presents as non-muscle-invasive BC (NMIBC) including Ta (non-invasive papillary carcinoma confined to the mucosa), CIS (Carcinoma in Situ, a flat, high grade, non-invasive urothelial carcinoma) and T1 (tumor invasion of the sub-epithelial connective tissue) disease stage. NMIBC has a high prevalence due to low progression rates and long-term survival, representing a significant burden on both public health and individual well-being. The prevalence of urothelial BC is among the highest for all urologic malignancies. Although the understanding of genetic susceptibility is growing steadily, no clinically relevant genetic alteration has been linked to BC up to date, and family history seems to have little impact on BC risk. Conversely, most BC cases are associated with external exposure to carcinogens. Supportive evidence has been reported on several risk factors: tobacco smoking alone accounts for approximately 50% of events. In contrast, occupational exposure (mostly involving aromatic amines, polycyclic, and chlorinated hydrocarbons) represents the second most common risk factor in industrialized countries. Environmental exposure (e.g., trihalomethanes and arsenic in drinking water) and pelvic radiation have been linked to an increased risk of developing BC. In light of the significant impact of modifiable risk factors on the incidence of BC, implementation of primary prevention strategies can lead to a decrease in BC risk: in the "Women's Health Initiative (WHI) Study" a decrease in BC risk was demonstrated after smoking cessation. Likewise, work-safety guidelines have been prompted to reduce the extent of professional exposure in developed industrial settings, thus eliminating the difference in BC incidence between chemical workers and the general population. Primary interventions targeting exposure and lifestyle changes have become central to public health strategies aimed at mitigating the burden of bladder cancer. In the broader landscape of primary prevention, dietary habits play a crucial role in reducing the risk of bladder cancer. Emerging evidence highlights the importance of nutrition in modulating cancer-related pathways, suggesting that specific dietary patterns and food choices may influence cancer risk. A protective role has been suggested for high consumption of vegetables, non-saturated fat oil (Mediterranean diet), fruits, and flavonoids. In contrast, a diet rich in saturated fats and meat has been linked to an increased risk of BC. Particularly, the consumption of vegetables of the Cruciferae family, such as broccoli, cauliflower, brussels sprouts, cabbage, kale, turnips, and others, has gathered attention for their potential protective effects due to their bioactive compounds: Isothiocyanates (ITCs). Dietary ITCs are a group of phytochemicals with multifaceted anticancer mechanisms primarily derived from cruciferous vegetables (CV) as glucosinolates and converted to ITCs by the action of the enzyme myrosinase. Organic ITCs, particularly allyl isothiocyanate (AITC), benzyl isothiocyanate (BITC), phenethyl isothiocyanate (PEITC), and sulforaphane (SF), are among the most extensively studied cancer chemopreventive agents. Several mechanisms for ITCs in protection against carcinogenesis have been proposed, which include inhibition of carcinogen activation and promotion of detoxification, induction of cell cycle arrest and activation of apoptosis, inhibition of cancer cell invasion, modulation of the tumor microenvironment, inhibition of self-renewal of stem cells, rearrangement of energy metabolism and regulation of microbial homeostasis. Several in vitro, in vivo, and epidemiologic studies have shown that a diet rich in vegetables in the Cruciferae family may lower overall cancer risk for breast, colorectal, lung, and prostate cancer. The important role of dietary ITCs has been demonstrated in reducing BC risk and BC-specific mortality. In vitro, the 4 most common dietary ITCs and their primary urinary metabolites showed inhibition of growth of a panel of human bladder cancer cells, including NMIBC cells, with half-maximal inhibitory concentration (IC50) values around 10 µmol on average, which is achievable in the urine with a single oral dose of ITC at 10 µmol/kg in rats, also readily achievable in humans, considering an average total isothiocyanate yield in Cruciferae of 16.2 μmol/100g wet weight. By increasing Cruciferae intake by 1 cup a day, the urinary concentration of ITCs increases on average by 10.4 µmol, the desirable dose level of urinary ITCs needed to stop or kill at least 50% of bladder cancer cells in in vitro models. Orally ingested ITCs are rapidly and almost exclusively delivered to the bladder and concentrated in the urine, showing concentration 2 or 3 times higher in the urine than in the plasma within 3 hours of dosing. This unique in vivo metabolism and disposition pathway renders the bladder the best target for ITCs' anticancer potential. In the Bladder Cancer Epidemiology, Wellness, and Lifestyle Study (Be-Well study), a multicenter prospective cohort study on newly diagnosed NMIBC, a possible beneficial role of dietary ITCs in NMIBC prognosis was assessed: despite no overall association between dietary ITC intake and recurrence risk was found, high ITC intake was linked to over twice the odds of late recurrence, while high raw cruciferous vegetable intake reduced the odds of multiple recurrences by 50%-60%, and elevated BITC and PEITC biomarkers were associated with >50% lower risk of muscle-invasive progression. In the same study group, the impact of dietary ITC exposure was assessed in relation to the efficacy of intravesical Mitomycin (MMC) chemotherapy or Bacillus Calmette-Guérin (BCG) immunotherapy on the risk of recurrence. In a stratified analysis, patients who received BCG and consumed high amounts (>2.4 servings/month with 1 serving corresponding to half a cup of non-leafy vegetables or 1 cup of leafy vegetables) of raw CVs had at least a 44% reduced risk of recurrence and multiple recurrences, which was not observed in those consuming low doses of row CV. In a randomized controlled setting, this study aims to assess the impact of CV intake and ITC exposure on recurrence risk in patients with NMIBC undergoing BCG intravesical immunotherapy.

Hypothesis Primary interventions targeting exposure and lifestyle changes have become central to public health strategies aimed at mitigating the burden of bladder cancer. In the broader landscape of primary prevention, dietary habits play a crucial role in reducing the risk of bladder cancer. Emerging evidence highlights the importance of nutrition in modulating cancer-related pathways, suggesting that specific dietary patterns and food choices may influence cancer risk. A protective role has been suggested for high consumption of vegetables, non-saturated fat oil (Mediterranean diet), fruits, and flavonoids. In contrast, a diet rich in saturated fats and meat has been linked to an increased risk of BC. Particularly, the consumption of vegetables of the Cruciferae family, such as broccoli, cauliflower, brussels sprouts, cabbage, kale, turnips, and others, has gathered attention for their potential protective effects due to their bioactive compounds: Isothiocyanates (ITCs). Dietary ITCs are a group of phytochemicals with multifaceted anticancer mechanisms primarily derived from cruciferous vegetables (CV) as glucosinolates and converted to ITCs by the action of the enzyme myrosinase. Organic ITCs, particularly allyl isothiocyanate (AITC), benzyl isothiocyanate (BITC), phenethyl isothiocyanate (PEITC), and sulforaphane (SF), are among the most extensively studied cancer chemopreventive agents. Several mechanisms for ITCs in protection against carcinogenesis have been proposed, which include inhibition of carcinogen activation and promotion of detoxification, induction of cell cycle arrest and activation of apoptosis, inhibition of cancer cell invasion, modulation of the tumor microenvironment, inhibition of self-renewal of stem cells, rearrangement of energy metabolism and regulation of microbial homeostasis.

Aims Primary Objective

  • To evaluate the effect, in terms of recurrence-free survival (RFS) at 1 year, of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, or Very High-grade Non-Muscle Invasive Bladder Cancer treated with BCG (defined as the standard of care - SOC).

Secondary Objectives

  • To evaluate the effect, in terms of time to recurrence, of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, and Very High-grade Non-Muscle Invasive Bladder Cancer.
  • To evaluate the effect, in terms of recurrence-free survival (RFS), of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, and Very High-grade Non-Muscle Invasive Bladder Cancer with prior recurrence ≤1/yr and \<4 tumors (according to 2016 EORTC risk stratification for patients treated with maintenance BCG).
  • To evaluate the impact of high Cruciferous vegetable consumption on urinary ITC levels.
  • To evaluate the impact of high Cruciferous vegetable consumption on quality of life (QoL).

Experimental design This study is a parallel-group, randomized controlled trial with a 1:1 allocation ratio designed to assess the superiority of a high-cruciferous vegetable dietary regimen compared to standard care in reducing bladder cancer recurrence.

Intervention The subjects will be assessed for eligibility at the screening visit (Visit 1) three weeks after TURB before randomization, and only subjects who fulfill the inclusion criteria will be included: patients with a diagnosis of Intermediate, High, and Very High-risk NMIBC, according to the new EAU NMIBC prognostic factor risk groups. Patients in the intervention group will receive a dietary regimen characterized by high consumption of Cruciferae vegetables [≥1 cup /day] for 6 months. Patients in this group will receive educative booklets on the Cruciferae family of vegetables and visual charts on serving sizing to meet the recommended daily CV intake. Patients will be asked to record daily Cruciferae intake. They will receive a live phone call every week to verify their understanding of the educational information and the consistency of the dietary regimen. Patients randomized in the control group will receive standard of care (SOC) without modifying the habitual nutritional regimen.

Study Timeline

Study Timeline Timepoint (mo) T0 1 2 3 4 5 6 7 8 9 10 11 12 ENROLMENT Eligibility screen X Informed Consent X Baseline clinical evaluation X Allocation X INTERVENTION Dietary Regimen vs SOC X X X X X X X ASSESSMENTS FU clinical evaluation X X X X FU phone call X X X X X X CLOSE-OUT X

Table 1. Study Timeline. Each participant will take part in the study for a total of 12 months after enrollment. Abbreviations: mo= months; FU= Follow-up.

Sample size A power analysis was conducted before data collection using SPSS to determine the appropriate sample size. A two-sided test with a Type I error rate (α) of 0.05 and a statistical power of 80% was performed to ensure adequate power for detecting a meaningful effect. The anticipated impact is the relative reduction of 40% (an absolute reduction of 10%) of the recurrence rate in the Study group versus the control group, given a recurrence rate in the general population (according to EAU risk stratification) of 25% at 1 year. To detect this difference, 250 patients per group are necessary, using the adjusted chi-square method.

Sequence generation and blinding The allocation sequence will be generated using computer-generated random numbers with a ratio of 1:1. This study will be conducted as an open-label trial. Due to the nature of the dietary intervention, neither participants nor study staff will be blinded to group assignment. However, outcome assessors analyzing urinary ITC levels and recurrence outcomes will be blinded to participant allocation.

Expected results The primary outcome of recurrence-free survival and the secondary outcome time to recurrence will be analyzed using Kaplan-Meier survival curves, and the intervention and control groups will be compared using the log-rank test. The Cox proportional hazards model will be applied to estimate hazard ratios, adjusting for relevant covariates such as age, gender, and baseline tumor characteristics. A two-tailed p-value \< 0.05 will be considered statistically significant. Secondary outcomes, including urinary ITC levels, will be analyzed using t-tests or Mann-Whitney U tests for continuous variables and Chi-squared tests for categorical variables, depending on the data distribution. Descriptive statistics (mean, median, standard deviation) will be provided for all continuous variables and frequencies for categorical variables. A subgroup analysis will be conducted in subjects with prior recurrence ≤1/yr and \<4 tumors (according to 2016 EORTC risk stratification for patients treated with maintenance BCG). An interim analysis will be conducted after 1 year of study enrollment to evaluate safety, efficacy, and trial progress.

Impact on cancer Low recurrence in bladder cancer

03

Conditions studied

  • Recurrence Free Survival
  • Bladder Cancer Recurrence

Browse trials for

Keywords

  • Bladder Cancer
  • NMIBC
  • Cruciferae
  • recurrence
04

In context

Non-Muscle Invasive Bladder Neoplasms Reclassified

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

This study's planned enrollment of 250 is above the median of 61 across 232 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Lead sponsor

S. Andrea Hospital is the lead sponsor of 17 studies on the registry; 3 are open to participants now.

Compared within Non-Muscle Invasive Bladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urinary Bladder Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed Non-Muscle Invasive Bladder Cancer of Intermediate, High, or Very High risk according to the 2021 EAU NMIBC scoring model.
  • Age ≥ 18

Exclusion criteria

Exclusion Criteria:

  • Low-Risk Non-Muscle Invasive Bladder Cancer
  • Muscle Invasive Bladder Cancer
  • \< 5 years
  • 3 or 4
  • Variant histology
  • Concomitant Urothelial Bladder Cancer in the Upper-Urinary Tract
  • Prostate or bladder radiotherapy
  • Urinary tract infection
  • Chronic urinary retention or indwelling catheters
  • Other ongoing oncological diseases
  • Active oncological treatments in the past 12 months
  • Persistent disease (defined as residual disease detected within three months after TURB or at first cystoscopy)
  • Specific dietary restrictions such as a vegetarian diet, celiac disease, or lactose intolerance
  • Chronic Kidney Disease
  • Chronic inflammatory diseases such as Crohn's disease or ulcerative colitis
  • History of gastric resection
  • Hepatic disorders such as cirrhosis or /AST levels three times above the upper normal limit
  • Thyroid disorders
  • Warfarin therapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    1 - Patients with Cruciferae intake diet

    Patients with Cruciferae intake diet

    Dietary Supplement: Cruciferae intake diet

  • Placebo comparator
    2

    Patients with normal diet

    Dietary Supplement: Habituary dietary regimen

Interventions

  • Dietary supplementCruciferae intake diet

    Patients in the intervention group will receive a dietary regimen characterized by high consumption of Cruciferae vegetables \[≥1 cup /day\] for 6 months. Patients in this group will receive educative booklets on the Cruciferae family of vegetables and visual charts on serving sizing to meet the recommended daily CV intake. Patients will be asked to record daily Cruciferae intake. They will receive a live phone call every week to verify their understanding of the educational information and the consistency of the dietary regimen.

  • Dietary supplementHabituary dietary regimen

    Patients randomized in the control group will receive standard of care (SOC) without any modification of the habitual dietary regimen.

07

What researchers measure

Primary outcomes

  1. Recurrence Free Survival

    of recurrence-free survival (RFS) at 1 year, of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, or Very High-grade Non-Muscle Invasive Bladder Cancer treated with BCG (defined as the standard of care - SOC).

    Time frame: 24 months

Secondary outcomes

  1. Recurrence in BCa

    Recurrence, of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, and Very High-grade Non-Muscle Invasive Bladder Cancer

    Time frame: 24 months

  2. ITC levels

    To evaluate the impact of high Cruciferous vegetable consumption on urinary ITC levels.

    Time frame: 24 months

08

Study locations

1 site
  • S.Andrea Hospital of Rome
    Rome, Lazio 00135, Italy
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2025
First posted
Feb 5, 2026
StartActual
Oct 17, 2025
Primary completionEst.
Nov 1, 2026
CompletionEst.
May 1, 2027
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07391137
Lead sponsor
S. Andrea Hospital
Responsible party
Cosimo De Nunzio (P.I. Professor, S. Andrea Hospital) — Principal investigator
First posted
Feb 5, 2026
Start date
Oct 17, 2025
Primary completion
Nov 1, 2026 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Feb 9, 2026

Study contacts

Cosimo De Nunzio, Professor
principal investigator · Sant'Andrea Hospital of Rome

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion